Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: CA9

Search for Biomarkers

Analyte:

CA9

Platform:

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ/ULOQ:

LLOQ: 4.47 pg/mL

Biological or Clinical Significance:

HumanMN/CA9gene is a novel member of the carbonic anhydrase (CA) family, which codes for widely distributed catalysts of the reversible conversion of carbon dioxide to carbonic acid. So far, MN/CA IX is the only tumor-associated CA isoenzyme. The entire genomic sequence ofMN/CA9,including the 5′-flanking region, encompasses 10.9 kb. The coding sequence is divided into 11 exons, whose organization and relationships to predicted protein domains suggest that the gene arose by exon shuffling.

Exon 1 encodes a signal peptide and a proteoglycan-related region. Exons 2–8 code for a CA domain with a highly conserved active site. The exon/intron pattern of the CA coding region is similar but not identical to other described animal kingdom α-CA genes. Exons 10 and 11 encode a transmembrane anchor and an intracytoplasmic tail, respectively. 

Sequence of the proximate 5′ end of the flanking region shows extensive homology to the long terminal repeats of HERV-K endogenous retroviruses. The putativeMN/CA9promoter immediately preceding the transcription start site does not possess a TATA box, but contains consensus sequences for the AP1, AP2, p53, and Inr transcription factors. This study will allow further investigations of the molecular events regulating expression of MN/CA IX as well as elucidation of its biological function.

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies